Chronic Myeloid Leukemia Clinical Trials

60 recruitingLast updated: June 17, 2026

There are 60 actively recruiting chronic myeloid leukemia clinical trials across 33 countries. Studies span Phase 2, Phase 1, Phase 3, Early Phase 1, Not Applicable. Top locations include Houston, Texas, United States, Seattle, Washington, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Chronic Myeloid Leukemia Trials at a Glance

60 actively recruiting trials for chronic myeloid leukemia are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 26 trials, with the heaviest enrollment activity in Houston, Seattle, and Chicago. Lead sponsors running chronic myeloid leukemia studies include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, and Novartis Pharmaceuticals.

Browse chronic myeloid leukemia trials by phase

Treatments under study

About Chronic Myeloid Leukemia Clinical Trials

Looking for clinical trials for Chronic Myeloid Leukemia? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Myeloid Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 60 trials

Recruiting

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

Chronic Lymphocytic Leukemia (CLL)Chronic Myeloid Leukemia, BCR-ABL1 PositiveDisease/Condition Name Cancer-related Cognitive Dysfunction
University of Rochester NCORP Research Base400 enrolled1 locationNCT07638007
Recruiting
Phase 2

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Chronic Myeloid Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT06236724
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 2

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+4 more
University of Florida20 enrolled1 locationNCT05800210
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled746 locationsNCT05334069
Recruiting
Early Phase 1

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+4 more
Omar Aljitawi24 enrolled1 locationNCT03964506
Recruiting
Phase 2

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Leukemia, MyeloidChronic Myeloid Leukemia, Chronic PhaseLeukemia,Myeloid, Chronic+1 more
University of Alabama at Birmingham100 enrolled7 locationsNCT05143840
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 1

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Chronic Myeloid LeukemiaMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics130 enrolled7 locationsNCT05362773
Recruiting
Phase 2

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT06817720
Recruiting
Phase 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting
Phase 1

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Advanced Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center30 enrolled1 locationNCT06401603
Recruiting
Phase 2

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Chronic Myeloid Leukemia (CML)
Novartis Pharmaceuticals20 enrolled6 locationsNCT06514534
Recruiting

Asciminib RMP Study

Chronic Myeloid Leukemia
Novartis Pharmaceuticals600 enrolled17 locationsNCT05943522
Recruiting
Phase 1Phase 2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled23 locationsNCT03934372
Recruiting
Phase 1

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+12 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT07166419
Recruiting
Phase 2

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

Chronic Myeloid Leukemia, Chronic Phase
Korean Society of Hematology69 enrolled1 locationNCT06368414
Recruiting
Phase 1

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Chronic Myeloid LeukemiaCMLChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Enliven Therapeutics250 enrolled45 locationsNCT05304377
Recruiting

Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China

Chronic Myeloid Leukemia in Chronic Phase
Novartis Pharmaceuticals200 enrolled1 locationNCT07375355
Recruiting
Phase 1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more
City of Hope Medical Center46 enrolled3 locationsNCT07020533